ClinicalTrials.gg
Drug

Maraviroc clinical trials

Also written Selzentry and Celsentri.

studies test it
118
open now
8
in phase 3
19
first study started
2002

How each study uses Maraviroc is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study

Get an email when these change. Save the Maraviroc studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.

Get alerts for these studies
See an example email

Example · made-up studies

Breast cancer · Recruiting: 2 came in, 3 changed

What changed in your alerts, Oct 31 – Nov 6:

A study of drug A after surgery for early breast cancer

Came in · now Recruiting

Drug B with hormone therapy in advanced breast cancer

Changed

· Sites: 4 added, including Seoul and Busan

· Enrollment: 300 → 450 participants

Exercise during chemotherapy

Now Active, not recruiting

One email a week for all your alerts. Stop any time.

Approvals

The first approval found in each region, with its record

United States
6 Aug 2007 · SELZENTRY · NDA 022128 (FDA, Drugs@FDA)
European Union
18 Sept 2007 · Celsentri · EMEA/H/C/000811 (EMA)

From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out

How studies write it

Studies that test it under each name

Name

Maraviroc
81
Selzentry, Celsentri
7
Maraviroc 300 mg
6
MVC
3
Maraviroc (MVC)
2

Brand

Selzentry
36
Celsentri
18

In one entry with another drug

Given together, or one or the other

Maraviroc + Fosamprenavir/ritonavir
2
lopinavir/ritonavir plus maraviroc
2

Studies by the year they started

117 studies that test it; most in 2009 (17)

Studies that test Maraviroc, by start year
YearStudies
20021
20031
20042
20076
200811
200917
201011
201112
201212
20134
20146
20158
20162
20178
20182
20191
20203
20212
20221
20231
20241
20252
20263

By phase

A phase 1/2 study counts in both.

Early Phase 1
1
Phase 1
30
Phase 2
37
Phase 3
19
Phase 4
33
No phase
8

What it is tested for

Each study’s main condition, where its own words name it, so a study counts once.

Who runs them

Industry 26 · Other 92

ViiV Healthcare (22) · National Institute of Allergy and Infectious Diseases (NIAID) (5) · University of California, San Francisco (4) · St Stephens Aids Trust (4) · University of Maryland, Baltimore (3) · Fundacion para la Investigacion Biomedica del Hospital Universitario Ramon y Cajal (3) · University of North Carolina, Chapel Hill (3) · Imperial College London (3)

Often tested with

Tested in the same studies.

Tenofovir (8) · Raltegravir (8) · Ritonavir (8) · Darunavir (7) · Emtricitabine (6) · Dolutegravir (4) · Fosamprenavir (3) · Etravirine (2)

Coming up

From the study records. Dates are the sponsors’ own estimates and often move.

Reaching primary completion within a year · 4, 1 in phase 3

Studies that test Maraviroc, phase 3 first.

Studies

Open first, then newest update. How each study uses Maraviroc is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.

Testing it · 118

See all 118 studies that test Maraviroc →

Given beside what is tested · 6 — Maraviroc is usual care or a partner of the new treatment
As the comparator · 2 — what is tested is compared with Maraviroc

Codes

What other systems call Maraviroc · ClinicalTrials.gg INT006766

  • MeSH (NLM) D000077592MaravirocConfirmed ClinicalTrials.gov, NLM, Wikidata
  • UNII (FDA) MD6P741W8AMARAVIROCConfirmed FDA, NLM, Wikidata
  • RxNorm 620216Confirmed FDA, Wikidata
  • Wikidata Q421369maravirocConfirmed FDA, NLM, Wikidata
  • NCI Thesaurus C73144MaravirocOne source FDA
  • DrugBank DB04835One source Wikidata

“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.